Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
3(25%)
Results Posted
100%(2 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_3
3
25%
Ph phase_2
4
33%
Ph phase_1
5
42%

Phase Distribution

5

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
5(41.7%)
Phase 2Efficacy & side effects
4(33.3%)
Phase 3Large-scale testing
3(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

12

all time

Status Distribution
Active(4)
Completed(2)
Terminated(2)
Other(4)

Detailed Status

unknown4
Completed2
Terminated2
Recruiting2
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
3
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (41.7%)
Phase 24 (33.3%)
Phase 33 (25.0%)

Trials by Status

completed217%
not_yet_recruiting18%
terminated217%
unknown433%
recruiting217%
active_not_recruiting18%

Recent Activity

3 active trials
Showing 5 of 12
active_not_recruitingphase_3

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958
not_yet_recruitingphase_3

SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC

NCT07549399
recruitingphase_1

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

NCT06445062
completedphase_1

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

NCT04660812
recruitingphase_2

SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer

NCT06908031
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04793958Phase 3

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Active Not Recruiting
NCT07549399Phase 3

SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC

Not Yet Recruiting
NCT06445062Phase 1

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Recruiting
NCT04660812Phase 1

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Completed
NCT06908031Phase 2

SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer

Recruiting
NCT03618758Phase 1

Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6

Completed
NCT03954704Phase 1

Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors

Terminated
NCT04310176Phase 2

Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer

Unknown
NCT04233151Phase 3

QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety

Unknown
NCT05193292Phase 2

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Unknown
NCT02226380Phase 2

FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer

Unknown
NCT00779311Phase 1

A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer

Terminated

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12